Yasuto Yoneshima

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières et al. · The Lancet · 2023 · 566 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Hirotsugu Kenmotsu, Kazushige Wakuda, Keita Mori et al. · Journal of Thoracic Oncology · 2022 · 158 citations

Medicine, Oncology, Pharmacotherapy +8

Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC

Yasuto Yoneshima, Satoshi Morita, Masahiko Ando et al. · Journal of Thoracic Oncology · 2021 · 106 citations · Full text

Pharmacy, Oncology, Pharmacology +9

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements

Yasuto Yoneshima, Kayo Ijichi, Satoshi Anai et al. · Lung Cancer · 2018 · 98 citations

Medicine, Molecular Biology, Oncology +17

Clinical impact of probiotics on the efficacy of <scp>anti‐PD</scp>‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting

Kazuki Takada, Mototsugu Shimokawa, Shinkichi Takamori et al. · International Journal of Cancer · 2021 · 96 citations · Full text

Medicine, Oncology, Pharmacotherapy +14